{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:01:10Z","timestamp":1649077270511},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13643-018-0838-y","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T06:02:26Z","timestamp":1540015346000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis"],"prefix":"10.1186","volume":"7","author":[{"given":"Christian","family":"Ovesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Purrucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"key":"838_CR1","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:160S\u201398S.","journal-title":"Chest"},{"key":"838_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","volume":"1","author":"F Bjorck","year":"2016","unstructured":"Bjorck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sjalander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol. 2016;1:172\u201380.","journal-title":"JAMA Cardiol"},{"key":"838_CR3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1503\/cmaj.061523","volume":"176","author":"N Oake","year":"2007","unstructured":"Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ. 2007;176:1589\u201394.","journal-title":"CMAJ"},{"key":"838_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1503\/cmaj.080171","volume":"179","author":"N Oake","year":"2008","unstructured":"Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179:235\u201344.","journal-title":"CMAJ"},{"key":"838_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/heartjnl-2016-309402","volume":"102","author":"K Adelborg","year":"2016","unstructured":"Adelborg K, Grove EL, Sundboll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart. 2016;102:1883\u20139.","journal-title":"Heart"},{"key":"838_CR6","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA Lopez-Lopez","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.","journal-title":"BMJ"},{"key":"838_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcac.2015.06.007","volume":"1","author":"K Oktay","year":"2015","unstructured":"Oktay K. Will NOACs become the new standard of care in anticoagulation therapy? Int J Cardiovasc Acad. 2015;1:1\u20134.","journal-title":"Int J Cardiovasc Acad"},{"key":"838_CR8","doi-asserted-by":"publisher","unstructured":"Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;8 \n                    https:\/\/doi.org\/10.1002\/14651858.CD14008980.pub14651852\n                    \n                  .","DOI":"10.1002\/14651858.CD14008980.pub14651852"},{"key":"838_CR9","doi-asserted-by":"publisher","unstructured":"Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev. 2015;12 \n                    https:\/\/doi.org\/10.1002\/14651858.CD14010957.pub14651852\n                    \n                  .","DOI":"10.1002\/14651858.CD14010957.pub14651852"},{"key":"838_CR10","doi-asserted-by":"publisher","unstructured":"Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014;3 \n                    https:\/\/doi.org\/10.1002\/14651858.CD14009893.pub14651852\n                    \n                  .","DOI":"10.1002\/14651858.CD14009893.pub14651852"},{"key":"838_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","volume":"26","author":"RA Al-Horani","year":"2016","unstructured":"Al-Horani RA, Desai UR. Factor XIa inhibitors: a review of the patent literature. Expert Opin Ther Pat. 2016;26:323\u201345.","journal-title":"Expert Opin Ther Pat"},{"key":"838_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232\u201340.","journal-title":"N Engl J Med"},{"key":"838_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11239-013-0958-0","volume":"37","author":"LR Jackson 2nd","year":"2014","unstructured":"Jackson LR 2nd, Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis. 2014;37:380\u201391.","journal-title":"J Thromb Thrombolysis"},{"key":"838_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamaneurol.2013.5433","volume":"71","author":"HB Brouwers","year":"2014","unstructured":"Brouwers HB, Chang Y, Falcone GJ, Cai X, Ayres AM, Battey TW, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol. 2014;71:158\u201364.","journal-title":"JAMA Neurol"},{"key":"838_CR15","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/STROKEAHA.108.520668","volume":"39","author":"B Cucchiara","year":"2008","unstructured":"Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P, Investigators C. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39:2993\u20136.","journal-title":"Stroke"},{"key":"838_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","volume":"164","author":"J Rosand","year":"2004","unstructured":"Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880\u20134.","journal-title":"Arch Intern Med"},{"key":"838_CR17","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","volume":"43","author":"D Dowlatshahi","year":"2012","unstructured":"Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43:1812\u20137.","journal-title":"Stroke"},{"key":"838_CR18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","volume":"66","author":"SM Davis","year":"2006","unstructured":"Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175\u201381.","journal-title":"Neurology"},{"key":"838_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1212\/WNL.0b013e318260cbba","volume":"79","author":"C Delcourt","year":"2012","unstructured":"Delcourt C, Huang Y, Arima H, Chalmers J, Davis SM, Heeley EL, et al. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology. 2012;79:314\u20139.","journal-title":"Neurology"},{"key":"838_CR20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1212\/WNL.0b013e3182143317","volume":"76","author":"D Dowlatshahi","year":"2011","unstructured":"Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76:1238\u201344.","journal-title":"Neurology"},{"key":"838_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1212\/01.WNL.0000133204.81153.AC","volume":"63","author":"R Leira","year":"2004","unstructured":"Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63:461\u20137.","journal-title":"Neurology"},{"key":"838_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.2015.0846","volume":"313","author":"JB Kuramatsu","year":"2015","unstructured":"Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824\u201336.","journal-title":"JAMA"},{"key":"838_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","volume":"101","author":"D Caldeira","year":"2015","unstructured":"Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Goncalves N, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101:1204\u201311.","journal-title":"Heart"},{"key":"838_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/1747493016681021","volume":"12","author":"C Marques-Matos","year":"2017","unstructured":"Marques-Matos C, Alves JN, Marto JP, Ribeiro JA, Monteiro A, Araujo J, et al. POST-NOAC: Portuguese observational study of intracranial hemorrhage on non-vitamin K antagonist oral anticoagulants. Int J Stroke. 2017;12:623\u20137.","journal-title":"Int J Stroke"},{"key":"838_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.amjcard.2016.04.034","volume":"118","author":"H Takahashi","year":"2016","unstructured":"Takahashi H, Jimbo Y, Takano H, Abe H, Sato M, Fujii Y, et al. Intracerebral hematoma occurring during warfarin versus non-vitamin K antagonist oral anticoagulant therapy. Am J Cardiol. 2016;118:222\u20135.","journal-title":"Am J Cardiol"},{"key":"838_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00701-016-3026-7","volume":"159","author":"C von der Brelie","year":"2017","unstructured":"von der Brelie C, Doukas A, Naumann R, Dempfle A, Larsen N, Synowitz M, et al. Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants. Acta Neurochir. 2017;159:101\u20139.","journal-title":"Acta Neurochir"},{"key":"838_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/WNL.0000000000002310","volume":"86","author":"D Wilson","year":"2016","unstructured":"Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology. 2016;86:360\u20136.","journal-title":"Neurology"},{"key":"838_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","volume":"73","author":"JC Purrucker","year":"2016","unstructured":"Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73:169\u201377.","journal-title":"JAMA Neurol"},{"key":"838_CR29","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","volume":"88","author":"D Wilson","year":"2017","unstructured":"Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017;88:1693\u2013700.","journal-title":"Neurology"},{"key":"838_CR30","doi-asserted-by":"publisher","first-page":"e0137444","DOI":"10.1371\/journal.pone.0137444","volume":"10","author":"J Skaistis","year":"2015","unstructured":"Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS One. 2015;10:e0137444.","journal-title":"PLoS One"},{"key":"838_CR31","first-page":"149","volume":"8","author":"M Franchini","year":"2010","unstructured":"Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149\u201354.","journal-title":"Blood Transfus"},{"key":"838_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","volume":"154","author":"D Keeling","year":"2011","unstructured":"Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154:311\u201324.","journal-title":"Br J Haematol"},{"key":"838_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.7326\/0003-4819-135-6-200109180-00008","volume":"135","author":"EM Hylek","year":"2001","unstructured":"Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001;135:393\u2013400.","journal-title":"Ann Intern Med"},{"key":"838_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1477-9560-6-15","volume":"6","author":"S Schulman","year":"2008","unstructured":"Schulman S, Elbazi R, Zondag M, O'Donnell M. Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J. 2008;6:15.","journal-title":"Thromb J"},{"key":"838_CR35","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1001\/archinte.163.20.2469","volume":"163","author":"A Lubetsky","year":"2003","unstructured":"Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:2469\u201373.","journal-title":"Arch Intern Med"},{"key":"838_CR36","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1592\/phco.20.15.1159.34585","volume":"20","author":"RJ Patel","year":"2000","unstructured":"Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000;20:1159\u201366.","journal-title":"Pharmacotherapy"},{"key":"838_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","volume":"115","author":"HG Watson","year":"2001","unstructured":"Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115:145\u20139.","journal-title":"Br J Haematol"},{"key":"838_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/00000542-199603000-00032","volume":"84","author":"Practice Guidelines for blood component therapy","year":"1996","unstructured":"Practice Guidelines for blood component therapy. A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732\u201347.","journal-title":"Anesthesiology"},{"key":"838_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2396987317699144","volume":"2","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Steiner T, Caso V, Wahlgren N. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13\u201315 November 2016. European Stroke J. 2017;2:95\u2013102.","journal-title":"European Stroke J"},{"key":"838_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0049-3848(02)00402-4","volume":"108","author":"M Yasaka","year":"2002","unstructured":"Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25\u201330.","journal-title":"Thromb Res"},{"key":"838_CR41","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jth.13212","volume":"14","author":"AL Marshall","year":"2016","unstructured":"Marshall AL, Levine M, Howell ML, Chang Y, Riklin E, Parry BA, et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost. 2016;14:324\u201330.","journal-title":"J Thromb Haemost"},{"key":"838_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/acem.12911","volume":"23","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med. 2016;23:466\u201375.","journal-title":"Acad Emerg Med"},{"key":"838_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12028-014-9972-0","volume":"21","author":"JA Frontera","year":"2014","unstructured":"Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care. 2014;21:397\u2013406.","journal-title":"Neurocrit Care"},{"key":"838_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/imj.12034","volume":"43","author":"HC Hanger","year":"2013","unstructured":"Hanger HC, Geddes JA, Wilkinson TJ, Lee M, Baker AE. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J. 2013;43:308\u201316.","journal-title":"Intern Med J"},{"key":"838_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/CIRCULATIONAHA.113.001875","volume":"128","author":"M Hickey","year":"2013","unstructured":"Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation. 2013;128:360\u20134.","journal-title":"Circulation"},{"key":"838_CR46","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/01.STR.0000221786.81354.d6","volume":"37","author":"HB Huttner","year":"2006","unstructured":"Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465\u201370.","journal-title":"Stroke"},{"key":"838_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.wneu.2012.12.002","volume":"81","author":"CH Woo","year":"2014","unstructured":"Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2014;81:110\u20135.","journal-title":"World Neurosurg"},{"key":"838_CR48","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12185-017-2311-4","volume":"106","author":"S Kushimoto","year":"2017","unstructured":"Kushimoto S, Fukuoka T, Kimura A, Toyoda K, Brainsky A, Harman A, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study. Int J Hematol. 2017;106:777\u201386.","journal-title":"Int J Hematol"},{"key":"838_CR49","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","volume":"385","author":"JN Goldstein","year":"2015","unstructured":"Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077\u201387.","journal-title":"Lancet"},{"key":"838_CR50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234\u201343.","journal-title":"Circulation"},{"key":"838_CR51","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","volume":"15","author":"T Steiner","year":"2016","unstructured":"Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566\u201373.","journal-title":"Lancet Neurol"},{"key":"838_CR52","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573\u20139.","journal-title":"Circulation"},{"key":"838_CR53","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511\u201320.","journal-title":"N Engl J Med"},{"key":"838_CR54","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431\u201341.","journal-title":"N Engl J Med"},{"key":"838_CR55","first-page":"35","volume":"12","author":"TY Hu","year":"2016","unstructured":"Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35\u201344.","journal-title":"Vasc Health Risk Manag"},{"key":"838_CR56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131\u201341.","journal-title":"N Engl J Med"},{"key":"838_CR57","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413\u201324.","journal-title":"N Engl J Med"},{"key":"838_CR58","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141\u20132.","journal-title":"N Engl J Med"},{"key":"838_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.annemergmed.2015.04.036","volume":"67","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016;67:96\u2013105 e105.","journal-title":"Ann Emerg Med"},{"key":"838_CR60","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000448815","volume":"42","author":"M Laible","year":"2016","unstructured":"Laible M, Jenetzky E, Beynon C, Muller OJ, Sander P, Schuler S, et al. Adverse events following international normalized ratio reversal in intracerebral hemorrhage. Cerebrovasc Dis. 2016;42:446\u201354.","journal-title":"Cerebrovasc Dis"},{"key":"838_CR61","doi-asserted-by":"publisher","unstructured":"Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev. 2015;7 \n                    https:\/\/doi.org\/10.1002\/14651858.CD14010555.pub14651852\n                    \n                  .","DOI":"10.1002\/14651858.CD14010555.pub14651852"},{"key":"838_CR62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11239-017-1506-0","volume":"44","author":"MPA Brekelmans","year":"2017","unstructured":"Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017;44:118\u201329.","journal-title":"J Thromb Thrombolysis"},{"key":"838_CR63","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors: GRADE handbook for grading quality of evidence and strength of recommendations.: The GRADE Working Group. Available from \n                    guidelinedevelopment.org\/handbook\n                    \n                  .; Updated 2013."},{"key":"838_CR64","unstructured":"JPT H, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011): The Cochrane Collaboration; 2011. Available from \n                    https:\/\/training.cochrane.org\/handbook\n                    \n                  ."},{"key":"838_CR65","doi-asserted-by":"publisher","first-page":"j176","DOI":"10.1136\/bmj.j176","volume":"356","author":"A Lundh","year":"2017","unstructured":"Lundh A, Bero L. The ties that bind. BMJ. 2017;356:j176.","journal-title":"BMJ"},{"key":"838_CR66","first-page":"MR000033","volume":"2","author":"A Lundh","year":"2017","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2:MR000033.","journal-title":"Cochrane Database Syst Rev"},{"key":"838_CR67","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/aje\/kwj069","volume":"163","author":"LL Gluud","year":"2006","unstructured":"Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163:493\u2013501.","journal-title":"Am J Epidemiol"},{"key":"838_CR68","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135:982\u20139.","journal-title":"Ann Intern Med"},{"key":"838_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609\u201313.","journal-title":"Lancet"},{"key":"838_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16350","volume":"16","author":"J Savovic","year":"2012","unstructured":"Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012;16:1\u201382.","journal-title":"Health Technol Assess"},{"key":"838_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","volume":"272","author":"KF Schulz","year":"1994","unstructured":"Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA. 1994;272:125\u20138.","journal-title":"JAMA"},{"key":"838_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"838_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333:597\u2013600.","journal-title":"BMJ"},{"key":"838_CR74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","volume":"53","author":"JL Tang","year":"2000","unstructured":"Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000;53:477\u201384.","journal-title":"J Clin Epidemiol"},{"key":"838_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120.","journal-title":"BMC Med Res Methodol"},{"key":"838_CR76","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351\u201375.","journal-title":"Stat Med"},{"issue":"8","key":"838_CR77","doi-asserted-by":"publisher","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","volume":"6","author":"Ji Cheng","year":"2016","unstructured":"Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 2016;6.","journal-title":"BMJ Open"},{"key":"838_CR78","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/sim.6383","volume":"34","author":"O Kuss","year":"2015","unstructured":"Kuss O. Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless. Stat Med. 2015;34:1097\u2013116.","journal-title":"Stat Med"},{"key":"838_CR79","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2017.07.006","volume":"91","author":"T Sharma","year":"2017","unstructured":"Sharma T, Gotzsche PC, Kuss O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. J Clin Epidemiol. 2017;91:129\u201336.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"838_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.536","volume":"102","author":"G Castellini","year":"2016","unstructured":"Castellini G, Nielsen EE, Gluud C. Comment on: \u201cCell therapy for heart disease: Trial sequential analyses of two Cochrane reviews\u201d. Clin Pharmacol Ther. 2016;102:21\u20134.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"838_CR81","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61:763\u20139.","journal-title":"J Clin Epidemiol"},{"key":"838_CR82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","volume":"38","author":"K Thorlund","year":"2009","unstructured":"Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009;38:276\u201386.","journal-title":"Int J Epidemiol"},{"key":"838_CR83","volume-title":"User manusal for trial sequential analysis (TSA)","author":"K Thorlund","year":"2011","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manusal for trial sequential analysis (TSA). Denmark: Copenhagen Trial Unit; 2011. Available from \n                    http:\/\/www.ctu.dk"},{"key":"838_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.","journal-title":"BMC Med Res Methodol"},{"key":"838_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375.","journal-title":"J Clin Epidemiol"},{"key":"838_CR86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-9-86","volume":"9","author":"J Wetterslev","year":"2009","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9:86.","journal-title":"BMC Med Res Methodol"},{"key":"838_CR87","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582\u201392.","journal-title":"Med Care"},{"key":"838_CR88","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.7326\/0003-4819-130-12-199906150-00019","volume":"130","author":"SN Goodman","year":"1999","unstructured":"Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med. 1999;130:1005\u201313.","journal-title":"Ann Intern Med"},{"key":"838_CR89","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1191\/1740774505cn098oa","volume":"2","author":"SN Goodman","year":"2005","unstructured":"Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2:282\u201390 discussion 301\u2013284, 364\u2013278.","journal-title":"Clin Trials"},{"key":"838_CR90","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-14-34","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34.","journal-title":"BMC Med Res Methodol"},{"key":"838_CR91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2017.02.010","volume":"84","author":"TL Nguyen","year":"2017","unstructured":"Nguyen TL, Collins GS, Lamy A, Devereaux PJ, Daures JP, Landais P, et al. Simple randomization did not protect against bias in smaller trials. J Clin Epidemiol. 2017;84:105\u201313.","journal-title":"J Clin Epidemiol"},{"key":"838_CR92","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017;17:162.","journal-title":"BMC Med Res Methodol"},{"key":"838_CR93","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/eb-2014-101900","volume":"17","author":"D Mavridis","year":"2014","unstructured":"Mavridis D, Chaimani A, Efthimiou O, Leucht S, Salanti G. Addressing missing outcome data in meta-analysis. Evid Based Ment Health. 2014;17:85\u20139.","journal-title":"Evid Based Ment Health"},{"key":"838_CR94","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"GUSTO investigators","year":"1993","unstructured":"investigators GUSTO. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673\u201382.","journal-title":"N Engl J Med"},{"key":"838_CR95","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774\u201382.","journal-title":"Circulation"},{"key":"838_CR96","doi-asserted-by":"publisher","unstructured":"Nielsen EE, Feinberg J, Greenhalgh J, Hounsome J, Sethi NJ, Safi S, et al. Drug-eluting stents versus bare-metal stents for stable ischaemic heart disease. Cochrane Database Syst Rev. 2016;12. \n                    https:\/\/doi.org\/10.1002\/14651858.CD012480\n                    \n                  .","DOI":"10.1002\/14651858.CD012480"},{"key":"838_CR97","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408\u201312.","journal-title":"JAMA"},{"key":"838_CR98","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","volume":"157","author":"J Savovic","year":"2012","unstructured":"Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157:429\u201338.","journal-title":"Ann Intern Med"},{"key":"838_CR99","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"838_CR100","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2337\/dc12-2449","volume":"36","author":"PD Home","year":"2013","unstructured":"Home PD. Validity of meta-analysis in diabetes: we need to be aware of its limitations. Diabetes Care. 2013;36:3361\u20137.","journal-title":"Diabetes Care"},{"key":"838_CR101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jrsm.1219","volume":"8","author":"M Bennetts","year":"2017","unstructured":"Bennetts M, Whalen E, Ahadieh S, Cappelleri JC. An appraisal of meta-analysis guidelines: how do they relate to safety outcomes? Res Synth Methods. 2017;8:64\u201378.","journal-title":"Res Synth Methods"},{"key":"838_CR102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ahj.2008.03.002","volume":"156","author":"AV Hernandez","year":"2008","unstructured":"Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J. 2008;156:23\u201330.","journal-title":"Am Heart J"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-018-0838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-018-0838-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-018-0838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T19:22:38Z","timestamp":1571512958000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-018-0838-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1186\/s13643-018-0838-y","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"4 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"169"}}